Study of SHR-3167 Injection Effects in Adults 18 to 59 Years with Type 2 Diabetes

What this Trial Is About

This research aims to evaluate the behavior of SHR-3167, a drug being studied in people with type 2 diabetes. The study focuses on understanding how the drug is absorbed, distributed, metabolized, and its effects at steady state in adults aged 18 to 59 years who have had type 2 diabetes for at least six months. The study is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is a phase 1 interventional trial. Participants will receive SHR-3167 injection, and insulin degludec injection is also involved in the study treatments. The trial will monitor the drugs concentration over time, especially measuring the area under the concentration-time curve from 0 to 168 hours after administration. Safety aspects like adverse events and hypoglycemic episodes will be recorded between weeks 21 and 43. During the study, participants will undergo various assessments, including blood tests to measure drug levels and safety monitoring for side effects. Researchers will also check for hypoglycemic events and other adverse reactions. The total participation period includes these monitoring phases, providing detailed information on how SHR-3167 acts in the body and its safety profile.

A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes